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Abstract
Background: Studies examining herpesvirus-herpesvirus (cytomegalovirus (CMV)-Epstein-Barr
virus (EBV)) interactions are limited, and many of the studies have been clinical observations
suggesting such an interaction exists. This report aims to examine the in vitro susceptibilities of
BJAB-B1 and P3HR-1 cells (EBV positive Burkitt's lymphoma B-cell lines) to a CMV superinfection;
and show that EBV reactivation occurs after CMV superinfects these cell lines.
Results: The BJAB-B1 and P3HR-1 cells were observed to be susceptible to a CMV superinfection
by the detection of the major immediate early (MIE) viral transcript and protein (p52) expression.
The BZLF1 transcript was observed in both cell lines superinfected with CMV, indicating EBV
reactivation. BZLF1 protein was observed in the BJAB-B1 cells. Antigen detection was not
performed in the P3HR-1 cells.
Conclusion: The results from the in vitro superinfections support the in vivo studies suggesting a
CMV infection is related to an EBV reactivation and suggests that CMV may be important as a co-
factor in EBV pathogenesis in the immunocompromised patient.
Background
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV), in
immunocompetent individuals, are etiologically associat-
ed with infectious mononucleosis as well as other disease
presentations and malignancies [1,2]. Once a person has
recovered from an active herpesvirus infection, it will es-
tablish a latent infection. Maintenance of viral latency is
primarily determined by the immune status of the host;
but there are other factors that can contribute to herpesvi-
ral reactivation [3–7].
There are numerous studies observing CMV and EBV reac-
tivation in immunosuppressed patients. CMV is the most
important pathogen among these patients and the virus
can cause both direct and indirect effects [8–13]. Among
solid organ transplant recipients, the effects of CMV dis-
ease are similar among all patients, with the exception be-
ing the effect on the transplanted organ [10,14–17]. The
most common disease presentation of CMV in AIDS pa-
tients is retinitis [8,11]. The significance of CMV disease in
transplant and HIV infected individuals goes much fur-
ther than the direct pathological effects because CMV has
been shown to be an immune modulator and may con-
tribute significantly to the net immunosuppressive status
of the patient [11]. This immunomodulation would
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therefore increase the susceptibility to superinfections
from other pathogens.
Oral hairy leukoplakia, caused by EBV, can be present in
25% of HIV infected individuals [8,18]. Other clinical
presentations have been observed as well [8,19,20]. Birx et
al. observed that patients with AIDS or AIDS-related dis-
orders have a defect in the regulation of EBV infected B-
cells and these patients have high circulating numbers of
these infected cells [21]. Post-transplant lymphoprolifera-
tive disorder (PTLD) results from the uncontrolled lym-
phoproliferation of EBV infected B-cells in transplant
patients [22,23]. There are many known factors for the de-
velopment of PTLD, among which is the presence of an
active CMV infection [13,19,22–24].
Many studies have focused upon the presence of a single
herpesvirus in the transplant or AIDS patient [8–10].
There are fewer studies examining virus-virus interactions
and the effect they may have on each other. Although sev-
eral investigators have focused upon the relationship of
human herpesvirus-6 (HHV-6) (same herpesvirus sub-
family as CMV) and HIV [25–29], studies dealing with po-
tential herpesvirus-herpesvirus interactions are very
limited. Such studies would be interesting since CMV in-
fection has been suggested as a risk factor for the develop-
ment of PTLD [22,24]. Investigators have showed that a
large percentage of transplant patients who had devel-
oped PTLD also had CMV disease [22,30]. In addition to
CMV being implicated as a factor for the development of
PTLD, serological studies have shown that patients with
an active CMV infection experienced a serological profile
of EBV reactivation [22,31,32]. Cross reactivities between
the two viruses were ruled out as a cause for the observed
immunoreactivations.
One study performed in vitro superinfections of EBV posi-
tive cell lines (Akata, Raji, and P3HR-1) with HHV-6. EBV
reactivation was observed to occur in those cell lines that
were superinfected with HHV-6 and the authors hypothe-
sized that there was a direct effect of HHV-6 on EBV reac-
tivation [33]. A more recent study by Vieira et al. was able
to show human herpesvirus-8 (HHV-8) activation of lytic
replication by CMV [34]. HHV-8 is in the same herpesvi-
rus subfamily as EBV. The clinical studies do suggest that
there may be a relationship between CMV infection and
EBV reactivation, and the in vitro studies strengthen the
notion of potential herpesvirus-herpesvirus interactions
occurring. However, the effect CMV and EBV may have on
each other has not specifically been investigated. There-
fore this study examined an in vitro CMV superinfection of
EBV latently infected cell lines (BJAB-B1 and P3HR-1
cells) and the effect on EBV reactivation. These B-cell lines
were observed to be susceptible to a CMV superinfection
and EBV reactivation occurs only in the cell lines superin-
fected with CMV. The observations in this study support
the previous in vivo and in vitro findings by showing that
potential interactions exist between CMV and EBV. Over-
all, these data suggest CMV may be a cofactor in EBV
pathogenesis in the immunosuppressed patient.
Results
CMV transcript in BJAB-B1 and P3HR-1 cells
The CMV MIE transcript was present in the BJAB-B1 and
P3HR-1 cells superinfected with CMV at all time points as
shown by the real-time PCR data (Figures 1A and 2A, re-
spectively). CMV copy standards were run for calculation
of the standard curve. The CMV standards (5 ×  105, 5 ×
103, and 5 ×  101) for the BJAB-B1 cells are shown (Figure
1C) and the standards for the P3HR-1 cells were not
shown. Agarose gel analysis was run only with the BJAB-
B1 cells (Figure 1D) and the greatest amount of transcript
was observed at 24 hours post CMV superinfection with a
decline in the latter time points. BJAB-B1 and P3HR-1
cells that were exposed to UV-irradiated CMV had no pres-
ence of the CMV MIE transcript, indicating that the virus
was inactivated (Figures 1B and 2B, respectively). The un-
infected cell lines were negative for the CMV MIE tran-
script and show that the CMV primers do not cross-react
with EBV (data not shown). Table 1 (BJAB-B1) and Table
2 (P3HR-1) show the quantitative analyses calculated
from the standard curve. The calculated starting quantity
(SQ) values given in both tables suggest that these cell
lines, although they are susceptible to CMV, do not show
a high amount of infection. Mock RT-PCRs were per-
formed in which PCR grade water was substituted for the
RT enzyme. These mock reactions served as a check for
DNA contamination and the mock RT-PCRs of the respec-
tive experimental groups were negative (data not shown).
CMV antigen in P3HR-1 and BJAB-B1 cells
Immunofluorescent staining for the p52 antigen was per-
formed to further show the susceptibilities of CMV in the
BJAB-B1 and P3HR-1 cell lines. The p52 gene expresses a
DNA binding protein that is present in the nuclei of in-
fected cells beginning in the early phase of infection
through to the late phase. All time points for both cell
lines (BJAB-B1 and P3HR-1) were positive for p52 antigen
and a representative slide is shown at 24 hours post CMV
superinfection (Figure 3A and 4A, respectively). All BJAB-
B1 and P3HR-1 cells exposed to UV-irradiated CMV were
consistently negative for the p52 antigen indicating suffi-
cient CMV inactivation (Figures 3B and 4B, respectively).
The uninfected cells from both cell lines were also nega-
tive showing no cross-reactivities with CMV (data not
shown). Flow cytometric analysis was performed only
with the BJAB-B1 cells. Data from the flow experiments
were able to give a quantitative analysis by analyzing the
fluorescence of the individual cells. Positive cells were de-
termined by subtracting the background fluorescence ofBMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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the uninfected samples from either the superinfected cells
or cells exposed to inactivated virus. CMV p52 antigen ex-
pression (575 cells) was observed beginning at 72 hours
compared to a background staining of 77 cells that were
exposed to inactivated CMV. Three hundred seventy nine
and 150 p52 positive cells were present at 96 and 168
hours, respectively. The UV-irradiated CMV exposed cells
had counts of 34 and 76 cells (96 and 168 hours, respec-
tively). Positive counts in the BJAB-B1 cells exposed to in-
activated CMV represents non-specific staining. 10,000
cells were collected and analyzed per experimental group.
The flow cytometry data is summarized in Table 3. The
amount of CMV positive BJAB-B1 cells, as also observed in
the real-time data, show a decrease with respect to time.
Both the transcript data as well as the p52 antigen expres-
sion data show that the BJAB-B1 cells are susceptible to a
CMV superinfection and there was not a high amount of
infection. Qualitative analyses of the immunofluorescent
staining in BJAB-B1 and P3HR-1 cells also show that a low
amount of infection was occurring.
CMV undergoes an abortive infection in BJAB-B1 cells
A CMV abortive infection was not determined for the
P3HR-1 cells. In order to determine if CMV was undergo-
ing an abortive or replicative infection, separate CMV su-
perinfection experiments were performed. Cells were
washed after 5 hours incubation with CMV and fresh me-
dia was added. The CMV infections were carried out to 10
days. Supernatants were taken immediately after washing
to show absence of unattached CMV. Aliquots were taken
at 24 and 48 hours for immunofluorescence analysis to
confirm CMV infection (data not shown). After 10 days
the cells were vortexed and supernatant was collected and
placed into cultures of MRC-5 fibroblasts. MRC-5 infec-
tions were carried out to 10 days. No CPE was observed in
any of the fibroblast infections, suggesting that an abor-
tive infection was occurring in the BJAB-B1 cells.
Figure 1
Real-time PCR of the CMV MIE transcript in BJAB-B1 cells. In all graphs, the axes are relative fluorescence units
(RFUs) versus cycle number. Real-time PCR amplification of the CMV MIE transcript from superinfected BJAB-B1 cells was
performed using 5 µl of cDNA from the RT reactions. Time points are at the given designations C7 (24 hours), C8 (48 hours),
C9 (72 hours), C10 (96 hours), and C11 (168 hours) (A). Real-time PCR amplification of the CMV MIE transcript from BJAB-
B1 cells incubated with UV-irradiated CMV (B). All time points were negative at the given designations G1 (24 hours), G2 (48
hours), G3 (72 hours), G4 (96 hours), and G5 (168 hours). CMV DNA copy standards were run in order to establish a stand-
ard curve for quantitative analysis. A1 (500,000 copies), A2 (5,000 copies), A3 (50 copies), and A4 (negative control) (C). Aga-
rose (2%) gel electrophoresis of the real-time PCR samples was performed in order to show specificity of the PCR reactions.
Positive control is as indicated. Shown here are the real-time PCR samples of the BJAB-B1 cells superinfected with CMV. Lanes
1–5 correlate to the time points 24, 48, 72, 96, and 168 hours (D).BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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EBV reactivation after CMV superinfections of BJAB-B1 
and P3HR-1 cells
This project has shown that the BJAB-B1 and P3HR-1 cells
were susceptible to a CMV superinfection by detecting vi-
ral transcript and protein. The effect on EBV latency was
next examined. The BZLF1 gene product, Zebra (Zta) is an
indicator for EBV reactivation. PMA and ionomycin (1 µg/
ml) non-specifically reactivates EBV and was used as a
positive control for BZLF1 transcript expression in the cell
lines. The BJAB-B1 and P3HR-1 cells were incubated with
PMA/ionomycin (1 µg/ml) (Figures 5A and 6A, respec-
tively). Presence of the BZLF1 transcript in the superinfect-
ed P3HR-1 cells was observed beginning at 24 hours post
superinfection, decreased at 48 hours and then was ob-
served to increase after 72 hours (Figure 6B). Detection of
BZLF1 in the P3HR-1 cells was performed by real-time
PCR only. BZLF1 transcript in the BJAB-B1 cells was first
observed at 48 hours post CMV superinfection and was
expressed through to 96 hours, as shown in the real-time
PCR data (Figure 5B). The amount of BZLF1 transcript ex-
pression in the BJAB-B1 cells started to decrease after 48
hours. Agarose gel analysis confirms the real-time PCR
data and shows that the PCR was specific (Figure 6D).
Due to the relatively low amount of the BZLF1 PCR prod-
uct in the real-time data and gel analysis, it was expected
that the immunofluorescence staining would be minimal.
Immunofluorescence analysis was performed only with
the BJAB-B1 cells and the experimental group that was su-
Figure 2
Real-time PCR of the CMV MIE transcript in P3HR-1 cells. In all graphs, the axes are relative fluorescence units (RFUs)
versus cycle number. CMV DNA copy standards were run in order to establish a standard curve for quantitative analysis. A1
(500,000 copies), A2 (5,000 copies), A3 (50 copies), and A4 (negative control) (data not shown). cDNA from the P3HR-1 cells
were treated similarly to the BJAB-B1 cells. Shown are P3HR-1 cells superinfected with CMV (A) and cells exposed to UV-irra-
diated CMV (B). Uninfected cells were negative for any CMV transcript (data not shown). Time points are designated in the fig-
ure. For these set of experiments, 0, 24, 48, 72, 96, 120, and 168 hours post superinfection were performed. Agarose gel
analyses were not performed.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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perinfected with CMV was observed to have expression of
the BZLF1 protein at 168 hours (Figure 7A). BJAB-B1 cells
stimulated with PMA/ionomycin were used as a positive
IF control (Figure 7B). Uninfected and UV-irradiated CMV
treated cells showed no expression of the BZLF1 transcript
or protein indicating no EBV reactivation (data not
shown). Mock RT-PCRs were not performed for the BZLF1
PCR reactions because the primers recognize mRNA.
Glyceraldehyde-3-phosphate dehydrogenase (G3PDH)
Amplification of the housekeeping gene G3PDH served as
a control for RNA integrity. The product was analyzed by
agarose (2%) gel electrophoresis and stained with ethid-
ium bromide. This transcript was present at all time points
among all experimental groups for both cell lines (data
not shown).
Discussion
This study has shown that the BJAB-B1 and P3HR-1 cell
lines were susceptible to a CMV superinfection, and a low
amount of infection was observed. Numerous studies
have been able to show that PBMCs and B-cells in partic-
ular can have expression of viral transcript and/or antigen
[35–41] however, other studies have been contradictory
[40,42] and therefore no consensus among the observa-
tions noted. Early studies have shown that in other B-cell
lines, CMV DNA has been observed [43–45]. The MOI
used in this study (20) indicates that there were 20 virus
particles per BJAB-B1 or P3HR-1 cell. This high MOI
would have seemed to ensure that enough CMV was
present to superinfect the respective cell lines. However,
despite the high MOI, the real-time PCR and immunoflu-
orescent staining data from the BJAB-B1 and P3HR-1 cells
show low amounts of infection present.
The concept of this study was to show evidence that CMV
can superinfect these B-cell lines and may induce EBV re-
activation by using a standardized CMV preparation. In-
fectivity differences have been observed between clinical
isolates of CMV and laboratory adapted strains. The strain
used in this study, AD169, and the Towne strains were
both used to develop vaccines [49]. Differences in infec-
tivity have been observed between 2 of the same strains of
CMV and this may be attributed to the deletion or muta-
tion of certain tropism genes upon extensive serial propa-
gation [50,51]. Clinical isolates (wild-type CMV) can
carry more than 220 genes, and some of these genes can
Table 1: CMV quantities of standards and superinfected BJAB-B1 
cells.
Type Threshold Cycle
(TC)
Starting Quantity
(SQ)
A1 Standard 17.493 5.00 ×  105
A2 Standard 23.859 5.00 ×  103
A3 Standard 28.712 5.00 ×  101
C7 Unknown 32.02 4.07 ×  100
C8 Unknown 36.175 1.34 ×  10-1
C9 Unknown 35.825 1.79 ×  10-1
C10 Unknown 35.21 2.96 ×  10-1
C11 Unknown 35.139 3.14 ×  10-1
Data presented here were calculated from the standard curve with 
the included analysis software. C7, C8, C9, C10, and C11 corre-
sponded to the time points 24, 48, 72, 96, and 168 hours. The TC 
(threshold cycle) is the cycle number in which the fluorescence of the 
sample crosses the threshold line. The threshold level is a subjective 
analysis by placing the line when the samples were in its exponential 
phase of the PCR reactions. The software calculates the 'Starting 
Quantity' (SQ), which represents the input copies of cDNA.
Table 2: CMV quantities of superinfected P3HR-1 cells.
Type Threshold Cycle
(TC)
Starting Quantity
(SQ)
A1 standard 17.63 5.00 ×  105
A2 Standard 24.14 5.00 ×  103
A3 Standard 29 5.00 ×  101
D5 Unknown 31.75 1.98 ×  100
D6 Unknown 32.59 9.01 ×  10-1
D7 Unknown 29.19 2.17 ×  101
Data presented here were calculated from the standard curve with 
the included analysis software. D5, D6, and D7 correspond to 96, 120, 
and 168 hours. The TC (threshold cycle) is the cycle number in which 
the fluorescence of the sample crosses the threshold line. The thresh-
old level is a subjective analysis by placing the line when the samples 
were in its exponential phase of the PCR reactions. The software cal-
culates the 'Starting Quantity' (SQ), which represents the input copies 
of cDNA.
Table 3: Flow cytometry data of p52 antigen within BJAB-B1 
cells.
72 hr 96 hr 168 hr
CMV 575 379 150
uvCMV 77 34 76
Flow cytometry was performed on uninfected cells, cells infected with 
CMV, and cells incubated with UV-irradiated CMV. The background 
fluorescence of the uninfected cells was subtracted from the respec-
tive samples to give a final quantity of CMV positive cells. 'CMV' indi-
cates BJAB-B1 cells infected with viable CMV and 'uvCMV' indicates 
cells incubated with UV-irradiated virus. Time points are as indicated. 
Quantitative values are per 10,000 cells.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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Figure 3
Immunofluorescence of p52 antigen in BJAB-B1 cells
superinfected with CMV. Immunofluorescence staining
was performed to give a qualitative analysis of CMV protein
expression and to further show susceptibility of infection.
Approximately 50,000 BJAB-B1 cells for each experimental
group were subjected to a cytospin for antigen staining. The
cells were fixed in acetone and methanol (1:1) mixture and
stained with the appropriate dilution of the FITC labelled
antibody. Presence of the p52 antigen was positive at all time
points (24, 48, 72, 96, and 168 hours), slide shown is at 24
hours post CMV superinfection. Uninfected cells and cells
incubated with UV-irradiated CMV showed no presence of
the p52 antigen (data not shown). Positive control slides
(Chemicon, Temecula, CA) were stained with the antibody
to show that the antibody was working (data not shown).
Figure 4
Immunofluorescence of p52 antigen in P3HR-1 cells
superinfected with CMV. Immunofluorescence staining
was performed to give a qualitative analysis of CMV protein
expression and to further show susceptibility of infection.
Approximately 50,000 P3HR-1 cells for each experimental
group were subjected to a cytospin for antigen staining. The
cells were fixed in acetone and methanol (1:1) mixture and
stained with the appropriate dilution of the FITC labelled
antibody. Presence of the p52 antigen was positive at all time
points (24, 48, 72, 96, 120, and 168 hours), slide shown is at
24 hours post CMV superinfection. Uninfected cells and cells
incubated with UV-irradiated CMV showed no presence of
the p52 antigen (data not shown). Positive control slides
were stained with the antibody to show that the antibody
was working (data not shown).BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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be lost by deletion and/or rearrangement during laborato-
ry passage [50]. The AD169 strain used in this study has
been passaged many times and because of these variations
observed among the CMV strains, this may partly account
for the low infectivity observed in the BJAB-B1 and P3HR-
1 cells. Perhaps an increase in CMV infection in the cell
lines could have been obtained with the use of a clinical
isolate of CMV. Our laboratory is currently collecting clin-
ical isolates of CMV for future superinfection experiments.
The first step in CMV infection is attachment to its cellular
target; however, the receptors for CMV have not yet been
delineated. Heparin sulfate and CD13 have been suggest-
ed to be involved in CMV attachment [52–54]. Heparin
sulfate is a receptor present on many cell types, but CD13
is not expressed on B-cells. Even with these receptors be-
ing implicated as requirements for CMV adherence and
penetration, the wide range of cellular tropism observed
would suggest that additional receptors might be used.
The detection of CMV protein was performed to further
show CMV infection in the cell lines used. The CMV p52
antigen is expressed in the early phase of infection and in
the nuclei of infected cells. During a replicative infection,
expression of this protein continues through to the late
phase of infection [56]. One function of the p52 protein
is to aid in replication by binding to the viral DNA
polymerase. The immunofluorescence data confirms the
real-time PCR data showing that BJAB-B1 and P3HR-1
cells were susceptible to a CMV superinfection and a low
amount of infection was observed. The p52 expression as
shown in the flow cytometry data of the BJAB-B1 cells also
indicate that a low amount of infection was observed. The
numbers of p52 positive cells was also observed to de-
crease with respect to time, perhaps indicating an abortive
infection may be occurring. No CPE was observed in any
of the fibroblast superinfection studies indicating a lack of
extracellular CMV infectious particles. We did not test for
cell associated CMV in these experiments, so it is possible
that virus emerging from the infected B-cell line may be
bound to other cells in the culture. However, the fact that
only a small percentage of the B-cells showed evidence of
CMV infection along with the lack of virus in the superna-
tant supports the probability that the CMV infection of
the BJAB-B1 cells represents an abortive infection. The
data represented here support the work of others showing
Figure 5
BZLF1 Transcript Expression in BJAB-B1 Cells. BZLF1 transcript was chemically induced with PMA/ionomycin (1 µg/ml)
as a positive control for EBV reactivation. Qualitative real-time PCR was performed to show positive expression of the BZLF1
transcript. Time points were taken at 24 hours (C2), 48 hours (C9), and 72 hours (E2). E6 represents unstimulated cells and
also served as a negative control (A). Real-time PCR amplification of the BZLF1 transcript was performed using 5 µl of cDNA
from the RT reactions among BJAB-B1 cells superinfected with CMV. Time points are at the given designations A8 (24 hours),
A9 (48 hours), A10 (72 hours), A11 (96 hours), and A12 (168 hours) (B). Agarose (2%) gel electrophoresis of the real-time
PCR samples was performed in order to show specificity of the PCR reactions (C).BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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that CMV may undergo an abortive infection in B-cells
rather than a productive one [35,36,46–48].
Regardless of whether viable CMV or UV-irradiated CMV
is used, the virus still can attach to the host cell and cause
the upregulation of cellular genes, including proto-onco-
genes [55,57–59]. It was observed in this study that the
UV-irradiated CMV had no effect on BZLF1 transcript ex-
pression, suggesting that the effect observed in the super-
infected BJAB-B1 and P3HR-1 cells was not attachment
mediated and infectious CMV is at least required. At this
point it has not been determined if CMV acts directly or
indirectly to cause EBV reactivation. A direct effect would
imply that a CMV transactivator is produced that could
somehow cause the expression of or at least aid in the ac-
tivation of the BZLF1 gene. Flamand et al. observed that
HHV-6 (same subfamily as CMV) could cause the reacti-
vation of EBV [33]. The authors suggested that HHV-6 was
having a direct effect on EBV reactivation because they
were able to observe the presence of both viral antigens in
the same cell. However, this observation does not neces-
sarily suggest direct activation because the effect cellular
activation may have on EBV latency is not known. There
may be some as yet unknown host cell gene or genes that
are activated or upregulated in association with HHV-6
penetration and infection. Obviously the same uncertain-
ties can be applied to the CMV superinfections of the
BJAB-B1 and P3HR-1 cells.
Figure 6
BZLF1 transcript expression in P3HR-1 cells. BZLF1
transcript was chemically induced with PMA/ionomycin (1
µg/ml) as a positive control for EBV reactivation. Qualitative
real-time PCR was performed to show positive expression of
the BZLF1 transcript. Unstimulated cells served as a negative
control (A). Real-time PCR amplification of the BZLF1 tran-
script was performed using 5 µl of cDNA from the RT reac-
tions among P3HR-1 cells superinfected with CMV (B). Time
points are indicated in both (A) and (B).
Figure 7
Immunofluorescence of the BZLF1 protein in BJAB-
B1 cells. Immunofluorescence staining was performed to
show production of viral protein, indicative of EBV reactiva-
tion. Stimulated cells and approximately 50,000 experimental
sample cells were subjected to a cytospin and prepared simi-
larly to the p52 staining protocol. A secondary FITC-labelled
goat-anti-mouse antibody was used because the primary anti-
body was unlabelled. BJAB-B1 cells were stimulated with
PMA/ionomycin (1 µg/ml) for the induction of the BZLF1
protein and for a positive control (A). Presence of the BZLF1
protein was observed within the CMV superinfected BJAB-
B1 cells and only at 168 hours (B)BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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The BZLF1 gene of EBV is an immediate early gene in-
volved in the first step of EBV reactivation, and its activity
is controlled at the transcriptional level [60–66], by pro-
tein-protein interactions [64–68], and phosphorylation
[64,69,70]. Perhaps CMV may cause the activation of cer-
tain cellular kinases, which in turn may activate BZLF1
transcript expression. CMV has been shown to cause calci-
um flow and protein kinase C (PKC) activation that could
then be involved in the early activation of transcription
factors [71]. Cellular levels of secondary messengers inosi-
tol 1,4,5-triphosphate and 1,2-diacylglycerol [71–73], as
well as the MAP kinases (ERK1 and ERK2) [74,75] are also
known to be upregulated, which may have an effect on
EBV reactivation. One study performed a DNA microarray
analysis on CMV infected cells and observed an upregula-
tion of 258 cellular mRNAs whose level changes were by
a factor of 4 or more after the onset of viral replication
[76]. The functions of some of these genes still remains
highly speculative, yet it gives an insight as to what poten-
tial roles these genes may play, particularly in EBV reacti-
vation.
The CMV transcript expression in BJAB-B1 cells was ob-
served beginning at 24 hours and was expressed through
to 168 hours. The BZLF1 transcript was observed begin-
ning at 48 hours and expressed though 96 hours. There
was a greater amount of CMV MIE transcript present com-
pared to the BZLF1 transcript in the BJAB-B1 cells. BZLF1
protein expression was observed only at 168 hours post
CMV superinfection. CMV p52 protein expression was ob-
served through 168 hours post superinfection (immun-
ofluorescence and flow cytometry data) and p52 positive
cells peaked at 72 hours (flow cytometry). Among the
P3HR-1 cells, the CMV transcript was also expressed from
96 hours to 168 hours; however, the viral load increases
with respect to time as opposed to the BJAB-B1 cells. Dur-
ing the earlier time points (24, 48, and 72 hours), the
sample curves have not yet crossed the threshold and
therefore were not included in the program's final quanti-
tative analysis. The BZLF1 transcript in the superinfected
P3HR-1 cells shows presence at 24 hours, decreases at sub-
sequent time points and finally peaks at 168 hours. Differ-
ences in the CMV and BZLF1 transcript expression
between the BJAB-B1 and P3HR-1 cells may be attributed
to the fact that these are different cell lines, despite the
presence of EBV. The kinetic expression of both viral tran-
scripts and proteins in the respective cell lines would seem
to suggest that CMV may be having an indirect effect on
EBV reactivation through the participation of cellular fac-
tors.
Despite the low infectivity of the BJAB-B1 and P3HR-1
cells by CMV, EBV reactivation was observed in the exper-
imental groups superinfected with CMV. The cell lines
that were exposed to UV-irradiated CMV had no indica-
tion of BZLF1 transcript or protein suggesting that the ef-
fect on EBV reactivation was not attachment mediated and
that infectious CMV was required. In vivo, it would be dif-
ficult to pinpoint one specific factor to cause the switch
from latency to lytic infection. However, in vitro, it was
most interesting to observe EBV reactivation only in the
cell lines that were superinfected with CMV.
A CMV infection, in vivo, can contribute to the net immu-
nosuppressive status of the immunocompromised patient
[11]. A CMV infection can result in the production of cer-
tain immune effector proteins (cytokines and chemok-
ines) that may affect latency in the EBV infected B-cells
[77]. The production of these cytokines and chemokines
from a CMV superinfected BJAB-B1 or P3HR-1 cell may af-
fect neighboring cells and therefore cause EBV reactiva-
tion, implying that CMV could be having an indirect effect
on EBV latency.
Conclusions
Because CMV infection and disease is such an important
concern among the immunosuppressed patient popula-
tions (transplant and HIV infected individuals), its in-
volvement in the reactivation of EBV must be considered.
This report has shown that BJAB-B1 and P3HR-1 cells,
both latently infected with EBV, were susceptible to a
CMV superinfection and only in the experimental groups
that were superinfected with CMV were there any indica-
tion of EBV reactivation. These data support the clinical
studies showing an in vivo relationship between a CMV ac-
tive infection and EBV reactivation. Although it would be
very difficult to prove that a CMV infection is the cause of
EBV reactivation in clinical situations due to the gamut of
factors that are involved, the fact that EBV reactivation was
observed after in vitro CMV superinfections supports this
role. Inducers of EBV replication are of importance be-
cause of the serious complications that are associated with
recurrent EBV infections, particularly in immunosup-
pressed individuals. Since a majority of the population is
seropositive for CMV, reactivation of CMV in immuno-
suppressed patients may further accentuate the reactiva-
tion of EBV therefore contributing to the proliferation of
EBV infected B-cells. The results in this project suggest that
CMV may contribute as a co-factor in EBV pathogenesis.
More detailed molecular studies are needed to examine
the direct and/or indirect effects CMV may have on EBV.
Materials and Methods
Cells and virus
P3HR-1 (ATCC) and BJAB-B1 cells (generously donated
by Dr. George Miller) are EBV latently infected B-cells kept
in RPMI 1640 medium (supplemented with 10% FBS and
an antibiotic-mycotic solution) (Gibco, Invitrogen Corp.,
Carlsbad, CA). The AD169 laboratory strain of CMV was
from the clinical virology laboratory (Tampa GeneralBMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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Hospital, Tampa, FL), and used for the superinfections.
CMV was grown and harvested from MRC-5 fibroblast
cultures (Biowhittaker, Walkersville, MD) and concentrat-
ed by ultra-centrifugation (28000 g for 60 minutes at
4°C). The CMV titer was determined using the shell vial
assay. Briefly, this is an immunofluorescence assay in
which 1:10 dilutions of the virus were prepared in shell vi-
als and incubated at 37°C overnight. The MRC-5 cells in
the shell vials were fixed and permeabilized for 15 min-
utes in methanol:acetone (1:1) and then washed in PBS
(Bartels Inc., Intracel Corp., Frederick, MD, reconstituted
in 1 liter of Millipore water, pH 7.0–7.6). The cells were
stained with a FITC labelled antibody directed against the
major immediate early antigen (MIE) (Chemicon, Temec-
ula, CA) and visualized using a fluorescent microscope.
Each green (positive) cell was counted as one viral parti-
cle.
CMV superinfection of the BJAB-B1 and P3HR-1 cells
500,000 cells were counted using the Cell-DYN 4000 (Ab-
bott Systems, Abbott Park, IL) and placed in a 24-well cul-
ture plate with RPMI 1640 medium. The P3HR-1 and
BJAB-B1 cells were infected at a multiplicity of infection
(MOI) of 20 and were either uninfected, infected, or ex-
posed to UV-irradiated virus. CMV was exposed to UVC
light for 2 hours in our biological safety cabinet. The ex-
periments were carried out for 7 days and samples were
taken at 24, 48, 72, 96, and 168 hours. Time points for the
P3HR-1 cells were the same except for an additional time
point at 120 hours. At each time point, cells were analyzed
by immunofluorescence and real-time reverse tran-
scriptase-polymerase chain reaction (RT-PCR). The P3HR-
1 cells were not subjected to flow cytometric analysis. Su-
perinfections were repeated three times and data shown
are representative experiments.
MRC-5 fibroblast infection of supernatants from CMV su-
perinfections
Separate superinfection experiments of the BJAB-B1 cells
were set up and were incubated with CMV for 5 hours to
allow for viral attachment. The cells were then washed to
remove any unattached virus and fresh medium was add-
ed. The CMV superinfections were carried out to 10 days.
The cultures were vortexed, supernatant was collected,
and added to cultures of MRC-5 fibroblasts. Supernatant
fluid was collected immediately after infection and wash-
ing to establish that any unattached CMV was not present.
MRC-5 fibroblasts were examined for CPE.
Immunofluorescent staining for p52 (CMV) and BZLF1 
(EBV)
Aliquots of 100 µl (approximately 50,000 cells) from each
experimental group were subjected to a cytospin and fixed
and permeabilized similarly to the shell vial assay. The
anti-p52 and anti-BZLF1 antibodies (Dako Corporation,
Carpinteria, CA) were prepared according to package in-
serts. Evan's Blue was added to the final p52 solution. The
p52 antibody was directly labelled with FITC (fluorescein
isothiocyanate) and did not require a secondary antibody
step. The BZLF1 antibody is unlabelled and required a sec-
ondary goat anti-mouse antibody labelled with FITC. The
secondary antibody was diluted 1:200 in PBS and Evan's
Blue was added. The primary and secondary antibodies
were incubated in a humidified chamber at 37°C for 30
minutes. The slides were washed in PBS after each incuba-
tion step, prepared with mounting media, and visualized
under a fluorescent microscope.
Flow cytometry of p52 antigen
Aliquots of 300 µl (approximately 150,000 cells) were
placed in 5-ml Falcon tubes and washed in PBS. The cells
were fixed and permeabilized with pre-made solutions
from Caltag Laboratories (Burlingame, CA) (Fix & Perm)
according to kit instructions. During the permeabilization
step, FITC-labelled antibody (p52) was added at a 1:5 di-
lution. Cells were washed in PBS and then 750 µl of para-
formaldehyde was added and read on the FACScalibur
flow cytometer (Becton Dickinson, Los Angeles, CA). Flu-
orescence parameters were set with regards to infected and
uninfected samples. CMV infected and uninfected MRC-5
fibroblasts were used as positive controls for viable CMV
and antibody staining. 10,000 BJAB-B1 cells were first sep-
arated according to size and granularity (forward vs. side
scatter) on a dot plot. Viable cells were then selected and
gated for further analysis on a histogram for FL1 (FITC,
p52 antigen) versus cell counts. The final histogram anal-
yses involved subtracting background of the correspond-
ing mock-infected cells from the BJAB-B1 cells
superinfected with CMV or UV-irradiated CMV. Analysis
was performed using the CellQuest software (Becton
Dickinson, Los Angeles, CA). The P3HR-1 cells were not
analysed by flow cytometry.
RNA extraction and isolation
The nucleic acid isolation was performed on an automat-
ed extractor from the Organon Tekinika Corporation
(Boxtel, Netherlands) and the extractions were performed
according to kit instructions modified from the method
by Boom et al. [78]. All reagents used for extractions were
from the company. Aliquots of 400 µl (approximately
200,000 cells) were used per experimental time point. The
final result was approximately 50 µl of nucleic acid in elu-
tion buffer. The nucleic acid samples were then subjected
to DNase treatment and RNA clean up with Ambion's
(Austin, TX) DNA-free kit following their provided proto-
col.
RNA quantitation
Using Ribogreen dye and RNA quantitation standards
from Molecular Probes (Eugene, OR), the amount of RNABMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/20
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in the experimental samples were calculated. Briefly, an
aliquot of the RNA samples were diluted 1:100 in TE buff-
er. RNA standards were prepared (4000, 2000, 1000, 500,
250, and 125 ng). The Ribogreen dye was diluted 1:200 in
TE buffer and 20 µl of the diluted RNA (standard or sam-
ple) was mixed with 20 µl of the diluted Ribogreen dye.
Samples and standards were placed in a microtiter plate
and read on the CytoFluor reader from Applied Biosys-
tems (Foster City, CA) (excitation 485 nm/20 nm and
emission 530 nm/25 nm). The standard curve and sample
quantitations were determined using an Excel spread-
sheet.
Reverse transcription
RNA for cDNA production was performed using Prome-
ga's (Madison, WI) random hexamers, RNAsin, RT buffer,
and RT enzyme. For each sample, the RNA (2 µg) was in-
itially incubated with the random hexamers (0.5 µg) and
enough PCR grade water to bring the volume up to 20 µl.
Incubation of the RNA and random hexamers was per-
formed at 95°C for 5 minutes and then held at 4°C. The
RT mix included 5.6 µl of 5X RT buffer, 0.02 mM of dNTPs
(with dTTP, not dUTP, Perkin Elmer, Foster City, CA),
14.22 units of AMV RT enzyme, and 20 units of RNAsin
per reaction. A total of 9.68 µl of the RT mix was added to
the RNA samples (with the random hexamers) and then
subjected to RT cycle conditions (42°C for 45 minutes,
95°C for 5 minutes and a 4°C hold). All incubations were
done on BioRad's iCycler (Richmond, CA). Mock RTs
were set up in which PCR grade water was substituted for
the RT enzyme as a check for DNA contamination.
Real-time PCR
The PCR mix per reaction included 10 µl SYBR Green buff-
er, 1.5 mM MgCl2, 1 µM dNTP mix (with dUTP), 0.5 µl
CMV primer mix, 2.5 units AmpliTaq gold, 0.05 units of
uracil-N-glycosylase (UNG, Epicentre, Madison, WI) that
had been diluted 1:10 in UNG buffer, and molecular
grade water to bring the volume up to 45 µl with the ad-
dition of 5 µl of cDNA or standard. The PCR reagents were
obtained from Perkin Elmer. The CMV primers, from Syn-
thetic Genetics, Inc. (San Diego, CA), amplify the MIE
gene. The BZLF1 primers recognize only mRNA and the
sequences are 5'-TTCCACAGCCTGCACCAGTG-3' and 5'-
GGCAGCAGCCACCTCACGGT-3' [79]. Primers were gen-
erated by Sigma Genosys (The Woodlands, TX). The CMV
PCR was quantitative and the BZLF1 PCR was qualitative.
The PCR consisted of 2 pre-incubation steps, 37°C/15
minutes and 95°C/10 minutes (for UNG activation and
UNG denaturation/Taq activation). The cycles for PCR
were 95°C/30 seconds, 55°C/30 seconds, and 72°C/30
seconds for 35 cycles. CMV DNA copy standards (Synthet-
ic Genetics, Inc.) were used to set up a standard curve.
Standards were 500000, 5000, and 50 CMV DNA copies.
Dilutions were set up using PCR grade water. The software
(Bio-Rad, Richmond, CA) calculated the standard curve as
well as determined the amount of CMV DNA in the super-
infected samples. Agarose (2%) gel electrophoresis was
performed in order to determine the specificity of the PCR
reactions in the BJAB-B1 cells only. Primers and positive
control for the glyceraldehyde-3-phosphate dehydroge-
nase housekeeping gene were from Clontech (BD Bio-
sciences Clontech, Palo Alto, CA). PCR recipe and
conditions were run according to the included protocol.
G3PDH transcripts from both cell lines were analyzed on
a 2% agarose gel only.
Real-time PCR analysis
The instrument camera took numerous fluorescence read-
ings during the annealing stages and displayed the average
reading for that particular cycle. At the end of the PCR cy-
cling, the base line fluorescence was calculated and all the
samples were normalized to zero. The threshold level (CT)
was set at a point when the standards or positive control
were in its respective exponential phase of amplification.
The CT value is the cycle number in which a sample's flu-
orescence crosses the set threshold level, and therefore is
called positive. During quantitative analysis, the standard
curve was calculated and the sample concentrations were
derived from the curve. All calculations were performed
with the included software.
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